On September 6, 2016, Danaher (DHR) announced that it has entered into a definitive agreement to acquire Cepheid (CPHD) for a total consideration of about $4 billion. Cepheid produces molecular diagnostic systems used in clinical settings to diagnose life-threatening diseases such as HIV (human immunodeficiency virus), hepatitis, tuberculosis, and certain types of cancer. Cepheid has the largest installed base of any molecular diagnostic (IHF) platform. Its broad test menu delivers systems for institutions and hospitals (XLV) of any sophistication. Cepheid will be integrated as an independent operating company into Danaher's diagnostics segment. Roche Diagnostics (RHHBY) is the number-one player in the molecular diagnostics arena and is one of Cepheid's key competitors.